Evotec SE（EVO）财务数据EVOEvotec SE

Evotec SE (EVO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Discovery & Preclinical Development, accounting for 76.5% of total sales, equivalent to $140.19M. Another important revenue stream is Just Evotec Biologics. Understanding this composition is critical for investors evaluating how EVO navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Evotec SE maintains a gross margin of -1.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -31.03%, while the net margin is -32.51%. These profitability ratios, combined with a Return on Equity (ROE) of -26.35%, provide a clear picture of how effectively EVO converts its operational activities into shareholder value.

In the context of the broader market, EVO competes directly with industry leaders such as OCS and ROMA. With a market capitalization of $554.41M, it holds a leading position in the sector. When comparing efficiency, EVO's gross margin of -1.10% stands against OCS's N/A and ROMA's 17.13%. Such benchmarking helps identify whether Evotec SE is trading at a premium or discount relative to its financial performance.

Evotec's financial performance shows a troubling trend with declining revenues and increasing net losses. In Q2 2026, the company reported revenues of €143.5 million, down from €171.2 million in Q2 2025, and a net income loss of -€54.2 million.